1-17 of 17
Sumithra J. Mandrekar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years

Richard M Stone, Jun Yin, Sumithra J Mandrekar, Axel Benner, Maral Saadati, Ilene A. Galinsky, Ben L. Sanford, Rebecca Teske, Susan M. Geyer, Thomas Prior, Sergio Amadori, Frederick R. Appelbaum, Joseph Brandwein, Konstanze Döhner, Gerhard Ehninger, Arnold Ganser, Rebecca B. Klisovic, Jürgen Krauter, Guido Marcucci, Bruno Medeiros, Dietger W. Niederwieser, Miguel A. Sanz, Richard F. Schlenk, Hubert Serve, Jorge Sierra, Martin S. Tallman, Andrew H Wei, Theo J.M. de Witte, Christian Thiede, Hartmut Döhner, Richard A. Larson
Journal: Blood
Blood (2024) 144 (Supplement 1): 218.
https://doi.org/10.1182/blood-2024-201058
Published: 2024
Journal Articles

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

CME Clinical Trials & Observations
Jennifer A. Woyach, Gabriela Perez Burbano, Amy S. Ruppert, Cecelia Miller, Nyla A. Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry A. Rogers, Sameer A. Parikh, Deborah M. Stephens, Jennifer R. Brown, Gerard Lozanski, James Blachly, Sreenivasa Nattam, Richard A. Larson, Harry Erba, Mark Litzow, Selina Luger, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Richard F. Little, Shira Dinner, Richard M. Stone, Geoffrey Uy, Wendy Stock, Sumithra J. Mandrekar, John C. Byrd
Journal: Blood
Blood (2024) 143 (16): 1616–1627.
https://doi.org/10.1182/blood.2023021959
Published: 2024
Includes: Supplemental data
Journal Articles

Race-Ethnic Enrollment Disparities over 15 Years of Alliance/CALGB Acute Myeloid Leukemia Clinical Trials, Biobanks, and Correlative Science Protocols

Andrew Hantel, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, Wendy Stock, Sawyer Jacobson, Sumithra J Mandrekar, Richard M. Stone, Daniel J. DeAngelo, John C. Byrd, Gregory A. Abel
Journal: Blood
Blood (2021) 138 (Supplement 1): 111.
https://doi.org/10.1182/blood-2021-146607
Published: 2021
Journal Articles

Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial

Inhye E. Ahn, Amy S. Ruppert, Adrian Wiestner, James S. Blachly, John C. Byrd, Richard M. Stone, Sumithra J Mandrekar, Jennifer A. Woyach
Journal: Blood
Blood (2021) 138 (Supplement 1): 2642.
https://doi.org/10.1182/blood-2021-153822
Published: 2021
Journal Articles

A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Jennifer A. Woyach, Amy S. Ruppert, Gabriela Perez, Allison M Booth, Diane Feldman, Elie G Dib, Aminah Jatoi, Jennifer Le-Rademacher, Nyla A. Heerema, Cecelia Miller, Gerard Lozanski, Richard F. Little, Brian T. Hill, Wei Ding, Richard M. Stone, Sumithra J Mandrekar, John C. Byrd
Journal: Blood
Blood (2021) 138 (Supplement 1): 3728.
https://doi.org/10.1182/blood-2021-151471
Published: 2021
Journal Articles

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry Rogers, Sameer A. Parikh, Steven Coutre, Gerard Lozanski, Sreenivasa Nattam, Richard A. Larson, Harry P. Erba, Mark R. Litzow, James S. Blachly, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Jennifer R Brown, Richard F. Little, Scott E. Smith, Richard M. Stone, Sumithra J Mandrekar, John C. Byrd
Journal: Blood
Blood (2021) 138 (Supplement 1): 639.
https://doi.org/10.1182/blood-2021-153146
Published: 2021
Journal Articles

A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

Matthew C. Cheung, MDMSc, Nicole Mittmann, PhD, Carolyn Owen, MDFRCPC, Nizar Abdel-Samad, MD, Graeme Fraser, Selay Lam, MDBSc,FRCPC, Michael Crump, MD, Catherine Sperlich, Richard van der Jagt, Stephen Couban, MDBSc, Jennifer A. Woyach, MD, Amy S. Ruppert, PhD, Allison M Booth, Sumithra J Mandrekar, PhD, Gail T. McDonald, Lois E. Shepherd, Anca Prica, MD, Hope Yen, Bingshu E. Chen, Annette E. Hay
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–30.
https://doi.org/10.1182/blood-2020-136692
Published: 2020
Journal Articles

Impact of NPM1 / FLT3 -ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

Clinical Trials & Observations
Konstanze Döhner, Christian Thiede, Nikolaus Jahn, Ekaterina Panina, Agnes Gambietz, Richard A. Larson, Thomas W. Prior, Guido Marcucci, Dan Jones, Jürgen Krauter, Michael Heuser, Maria Teresa Voso, Tiziana Ottone, Josep F. Nomdedeu, Sumithra J. Mandrekar, Rebecca B. Klisovic, Andrew H. Wei, Jorge Sierra, Miguel A. Sanz, Joseph M. Brandwein, Theo de Witte, Joop H. Jansen, Dietger Niederwieser, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Richard F. Schlenk, Arnold Ganser, Hubert Serve, Gerhard Ehninger, Sergio Amadori, Insa Gathmann, Axel Benner, Celine Pallaud, Richard M. Stone, Hartmut Döhner, Clara D. Bloomfield
Journal: Blood
Blood (2020) 135 (5): 371–380.
https://doi.org/10.1182/blood.2019002697
Published: 2020
Includes: Supplemental data
Journal Articles

Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Jennifer Woyach, MD, Amy S. Ruppert, MAS, PhD, Gabriela Perez, MS, Allison M Booth, Diane Feldman, Elie G Dib, MD, Aminah Jatoi, MD, Jennifer Le-Rademacher, PhD, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Richard Little, MD, Wei Ding, MD PhD, Brian T. Hill, MD, Richard M. Stone, MD, Sumithra J Mandrekar, PhD, John C. Byrd, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1751.
https://doi.org/10.1182/blood-2019-127102
Published: 2019
Journal Articles

Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202

Jennifer A. Woyach, MD, Amy S. Ruppert, MAS, PhD, Nyla A. Heerema, PhD, Weiqiang Zhao, MD PhD, Allison M Booth, Wei Ding, MD PhD, Nancy L. Bartlett, MD, Danielle M. Brander, MD, Paul Barr, MD, Kerry A. Rogers, MD, Sameer A. Parikh, MD, Steven Coutre, MD, Arti Hurria, MD, Gerard Lozanski, MD, Sreenivasa Nattam, MD, Richard A. Larson, MD, Harry P. Erba, MDPhD, Mark R. Litzow, MD, Carolyn Owen, Jim Atkins, Jeremy S. Abramson, MD MMSc, Richard F. Little, MD MPH, Scott E. Smith, MD PhD, Richard M. Stone, MD, Sumithra J Mandrekar, PhD, John C. Byrd, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 6.
https://doi.org/10.1182/blood-2018-99-116653
Published: 2018
Journal Articles

Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614)

Jun Yin, PhD, Geoffrey L. Uy, MD, Betsy Laplant, MS, Elizabeth Storrick, Guido Marcucci, Hugo F. Fernandez, MD, Zhuoxin Sun, PhD, Mark R. Litzow, MD, Megan Othus, PhD, Frederick R. Appelbaum, MD, Richard A. Larson, MD, Richard M. Stone, MD, Sumithra J Mandrekar, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1386.
https://doi.org/10.1182/blood-2018-99-113902
Published: 2018
Journal Articles

Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study

Konstanze Döhner, MD, Christian Thiede, MD, Richard A. Larson, MD, Thomas W Prior, MD, Guido Marcucci, MD, Dan Jones, MD, Jürgen Krauter, MD, Michael Heuser, MD, Francesco Lo Coco, MD, Tiziana Ottone, PhD, Josep Nomdedeu, Sumithra J Mandrekar, PhD, Ben L. Sanford, MS, Kristine Laumann, Susan M. Geyer, PhD, Rebecca B. Klisovic, MD, Andrew Wei, MBBS, PhD FRACP, FRCPA, Jorge Sierra, Miguel A. Sanz, MD, Joseph M. Brandwein, MD FRCPC, T. M. M de Witte, MD PhD, Joop H. Jansen, Dietger Niederwieser, MD, Frederick R. Appelbaum, MD, Bruno C Medeiros, MD, Martin S. Tallman, MD, Richard F. Schlenk, MD, Arnold Ganser, MD, Hubert Serve, Gerhard Ehninger, Sergio Amadori, MD, Yuan Cheng, PhD, Celine Pallaud, PhD, Richard M. Stone, MD, Hartmut Döhner, MD, Clara D. Bloomfield, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 467.
https://doi.org/10.1182/blood.V130.Suppl_1.467.467
Published: 2017
Journal Articles

The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Richard M. Stone, MD, Sumithra J Mandrekar, PhD, Ben L. Sanford, MS, Kristine Laumann, Susan M. Geyer, PhD, Clara D. Bloomfield, MD, Konstanze Dohner, MD, Christian Thiede, MD, Guido Marcucci, MD, Francesco Lo Coco, MD, Rebecca B. Klisovic, MD, Andrew Wei, MBBS, PhD FRACP, FRCPA, Jorge Sierra, Miguel A. Sanz, MD, Joseph M. Brandwein, MD FRCPC, T. M. M de Witte, MD PhD, Dietger Niederwieser, MD, Frederick R. Appelbaum, MD, Bruno C Medeiros, MD, Martin S. Tallman, MD, Jurgen Krauter, MD, Richard F. Schlenk, MD, Arnold Ganser, MD, Hubert Serve, Gerhard Ehninger, Sergio Amadori, MD, Hartmut Dohner, MD, Richard A. Larson, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2580.
https://doi.org/10.1182/blood.V130.Suppl_1.2580.2580
Published: 2017
Journal Articles

An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Richard A. Larson, MD, Sumithra J Mandrekar, PhD, Ben L. Sanford, MS, Kristine Laumann, Susan M. Geyer, PhD, Clara D. Bloomfield, MD, Christian Thiede, MD, Thomas W Prior, MD, Konstanze Dohner, MD, Guido Marcucci, MD, Francesco Lo Coco, MD, Rebecca B. Klisovic, MD, Andrew Wei, MBBS, PhD FRACP, FRCPA, Jorge Sierra, Miguel A. Sanz, MD, Joseph M. Brandwein, MD FRCPC, T. M. M de Witte, MD PhD, Dietger Niederwieser, MD, Frederick R. Appelbaum, MD, Bruno C Medeiros, MD, Martin S. Tallman, MD, Jurgen Krauter, MD, Richard F. Schlenk, MD, Arnold Ganser, MD, Hubert Serve, Gerhard Ehninger, Sergio Amadori, MD, Hartmut Döhner, MD, Richard M. Stone, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 145.
https://doi.org/10.1182/blood.V130.Suppl_1.145.145
Published: 2017
Journal Articles

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

Clinical Trials & Observations
Martha Q. Lacy, Jacob B. Allred, Morie A. Gertz, Suzanne R. Hayman, Kristen Detweiler Short, Francis Buadi, Angela Dispenzieri, Shaji Kumar, Philip R. Greipp, John A. Lust, Stephen J. Russell, David Dingli, Steven Zeldenrust, Rafael Fonseca, P. Leif Bergsagel, Vivek Roy, A. Keith Stewart, Kristina Laumann, Sumithra J. Mandrekar, Craig Reeder, S. Vincent Rajkumar, Joseph R. Mikhael
Journal: Blood
Blood (2011) 118 (11): 2970–2975.
https://doi.org/10.1182/blood-2011-04-348896
Published: 2011
Journal Articles

Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials.

Prashant Kapoor, MD, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD, Martha Q. Lacy, MD, David Dingli, M.D., PhD., Robert Kyle, M.D., Morie A. Gertz, MD, Philip . R Greipp, MD, Shaji Kumar, MD, Sumithra J. Mandrekar, PhD
Journal: Blood
Blood (2009) 114 (22): 615.
https://doi.org/10.1182/blood.V114.22.615.615
Published: 2009
Journal Articles

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma

Martha Q. Lacy, MD, Suzanne R. Hayman, Morie A. Gertz, Jacob B. Allred, Sumithra J. Mandrekar, Angela Dispenzieri, Stephen R. Zeldenrust, Shaji Kumar, Philip R. Greipp, John A. Lust, Stephen J Russell, Francis Buadi, Robert A. Kyle, Peter Leif Bergsagel, MD, Rafael Fonseca, MD, Vivek Roy, MD, FACP, Joseph Mikhael, MD, A. Keith Stewart, MBChB, MBA, S. Vincent Rajkumar
Journal: Blood
Blood (2008) 112 (11): 866.
https://doi.org/10.1182/blood.V112.11.866.866
Published: 2008